Literature DB >> 22014572

Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Changmeng Cai1, Housheng Hansen He, Sen Chen, Ilsa Coleman, Hongyun Wang, Zi Fang, Shaoyong Chen, Peter S Nelson, X Shirley Liu, Myles Brown, Steven P Balk.   

Abstract

Androgen receptor (AR) is reactivated in castration-resistant prostate cancer (CRPC) through mechanisms including marked increases in AR gene expression. We identify an enhancer in the AR second intron contributing to increased AR expression at low androgen levels in CRPC. Moreover, at increased androgen levels, the AR binds this site and represses AR gene expression through recruitment of lysine-specific demethylase 1 (LSD1) and H3K4me1,2 demethylation. AR similarly represses expression of multiple genes mediating androgen synthesis, DNA synthesis, and proliferation while stimulating genes mediating lipid and protein biosynthesis. Androgen levels in CRPC appear adequate to stimulate AR activity on enhancer elements, but not suppressor elements, resulting in increased expression of AR and AR repressed genes that contribute to cellular proliferation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014572      PMCID: PMC3225024          DOI: 10.1016/j.ccr.2011.09.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  37 in total

1.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Authors:  Jeff Holzbeierlein; Priti Lal; Eva LaTulippe; Alex Smith; Jaya Satagopan; Liying Zhang; Charles Ryan; Steve Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

2.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Authors:  C W Gregory; R T Johnson; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease.

Authors:  David R Bauman; Stephan Steckelbroeck; Michelle V Williams; Donna M Peehl; Trevor M Penning
Journal:  Mol Endocrinol       Date:  2005-09-22

4.  Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral prostate and seminal vesicles and in human hepatoma cells.

Authors:  L X Shan; M C Rodriguez; O A Jänne
Journal:  Mol Endocrinol       Date:  1990-11

5.  Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA.

Authors:  Bu B Yeap; Dominic C Voon; Julian P Vivian; Ross K McCulloch; Andrew M Thomson; Keith M Giles; Maria F Czyzyk-Krzeska; Henry Furneaux; Matthew C J Wilce; Jackie A Wilce; Peter J Leedman
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

6.  Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

Authors:  J A Kemppainen; M V Lane; M Sar; E M Wilson
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

7.  Autologous down-regulation of androgen receptor messenger ribonucleic acid.

Authors:  V E Quarmby; W G Yarbrough; D B Lubahn; F S French; E M Wilson
Journal:  Mol Endocrinol       Date:  1990-01

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.

Authors:  Shinta Cheng; Sabrina Brzostek; Suzanne R Lee; Anthony N Hollenberg; Steven P Balk
Journal:  Mol Endocrinol       Date:  2002-07

10.  Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.

Authors:  Long G Wang; Liliana Ossowski; Anna C Ferrari
Journal:  Oncogene       Date:  2004-07-01       Impact factor: 9.867

View more
  210 in total

1.  Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.

Authors:  Shiori Saito; Jiro Kikuchi; Daisuke Koyama; Shin Sato; Hiroo Koyama; Naoki Osada; Yoshiaki Kuroda; Koshi Akahane; Takeshi Inukai; Takashi Umehara; Yusuke Furukawa
Journal:  Clin Cancer Res       Date:  2018-12-05       Impact factor: 12.531

2.  Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Authors:  Bing Song; Su-Hong Park; Jonathan C Zhao; Ka-Wing Fong; Shangze Li; Yongik Lee; Yeqing A Yang; Subhasree Sridhar; Xiaodong Lu; Sarki A Abdulkadir; Robert L Vessella; Colm Morrissey; Timothy M Kuzel; William Catalona; Ximing Yang; Jindan Yu
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

3.  The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.

Authors:  Hongbo Wang; Ming Jiang; Hongmei Cui; Mengqian Chen; Ralph Buttyan; Simon W Hayward; Tsonwin Hai; Zhengxin Wang; Chunhong Yan
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

4.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

5.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.

Authors:  Vasundhra Kashyap; Shafqat Ahmad; Emeli M Nilsson; Leszek Helczynski; Sinéad Kenna; Jenny Liao Persson; Lorraine J Gudas; Nigel P Mongan
Journal:  Mol Oncol       Date:  2013-01-19       Impact factor: 6.603

6.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

7.  Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Authors:  Katja Jehle; Laura Cato; Antje Neeb; Claudia Muhle-Goll; Nicole Jung; Emmanuel W Smith; Victor Buzon; Laia R Carbó; Eva Estébanez-Perpiñá; Katja Schmitz; Ljiljana Fruk; Burkhard Luy; Yu Chen; Marc B Cox; Stefan Bräse; Myles Brown; Andrew C B Cato
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

Review 8.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

9.  Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.

Authors:  Changmeng Cai; Housheng Hansen He; Shuai Gao; Sen Chen; Ziyang Yu; Yanfei Gao; Shaoyong Chen; Mei Wei Chen; Jesse Zhang; Musaddeque Ahmed; Yang Wang; Eric Metzger; Roland Schüle; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cell Rep       Date:  2014-12-04       Impact factor: 9.423

10.  GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

Authors:  Bin He; Rainer B Lanz; Warren Fiskus; Chuandong Geng; Ping Yi; Sean M Hartig; Kimal Rajapakshe; John Shou; Liping Wei; Shrijal S Shah; Christopher Foley; Sue Anne Chew; Vijay K Eedunuri; Diego J Bedoya; Qin Feng; Takashi Minami; Constantine S Mitsiades; Anna Frolov; Nancy L Weigel; Susan G Hilsenbeck; Daniel G Rosen; Timothy Palzkill; Michael M Ittmann; Yongcheng Song; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.